Brief: Inflarx Announces New Pipeline Program – Oral C5AR Inhibitor
10/01/2022 12:38
Jan 10 (Reuters) -
* INFLARX ANNOUNCES NEW PIPELINE PROGRAM – ORAL C5AR INHIBITOR
* INFLARX NV - EXPECTS TO INITIATE A PHASE I PROGRAM IN SECOND HALF OF 2022
FOR
INF904
Source text for Eikon: ID:nGNXN9rfL
Further company coverage: [ ]
Recent news on Inflarx NV
See all newsBrief: Inflarx NV Files For Offerng Of Ordinary Shares, Size Not Disclosed - SEC Filing
Brief: InflaRx Reports Full Year 2025 Results And Highlights Key Achievements And Expected Milestones
Brief: Inflarx Announces Late-Breaker Oral Presentation On Vilobelimab Phase 3 Results In Pyoderma Gangrenosum At 2026 American Academy Of Dermatology Annual Meeting
Brief: Inflarx NV Executing 30% Workforce Reduction
Brief: Inflarx Provides Update On Phase 3 Data Analyses For Vilobelimab In Pyoderma Gangrenosum